Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Sudden Cardiac Death: Pharmacotherapy and Proarrhythmic Drugs: A Nationwide Cohort Study in Denmark

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Diabetes and the Risk of Sudden Cardiac Death

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Editorial Commentary: When should the patient with an inherited cardiac disease have an ICD?

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  3. Defibrillators for prevention from sudden cardiac death: is it that easy?-Authors' reply

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

Vis graf over relationer

OBJECTIVES: This study sought to describe the use of pharmacotherapy in a nationwide cohort of young patients with sudden cardiac death (SCD).

BACKGROUND: Several drugs have been associated with an increased risk of SCD and sudden arrhythmic death syndrome (SADS). It remains unclear how pharmacotherapy may contribute to the overall burden of SCD in the general population.

METHODS: This was a nationwide study that included all deaths that occurred between 2000 and 2009 and between 2007 and 2009 in people age 1 to 35 years and 36 to 49 years, respectively. Two physicians identified all SCDs through review of death certificates. Autopsy reports were collected. Pharmacotherapy prescribed within 90 days before SCD was identified in the Danish Registry of Medicinal Product Statistics.

RESULTS: We identified 1,363 SCDs; median age was 38 years (interquartile range: 29 to 45 years), and 72% (n = 975) were men. Autopsy was performed in 55%. Overall, 58% of SCD cases (n = 786) received at least 1 drug within 90 days before death. The most common drugs were analgesic drugs (n = 239; 18%), antihypertensive drugs (n = 234; 17%), and antibiotic drugs (n = 218; 16%). After multivariable adjustment, prescription of "brugadogenic" drugs or >1 QT-prolonging drug was associated with an increased risk of SADS compared with explained SCD (odds ratio: 2.16 [95% confidence interval: 1.12 to 4.17] and 2.91 [95% confidence interval: 1.46 to 5.81], respectively).

CONCLUSIONS: Pharmacotherapy was identified in 58% of the SCD cases. After multivariable adjustment, there was a 2- and 3-fold increased risk of SADS compared with explained SCD in patients receiving brugadogenic drugs or >1 QT-prolonging drug, respectively. Identification of high-risk patients is warranted to lower the burden of SCD.

OriginalsprogEngelsk
TidsskriftJACC. Clinical electrophysiology
Vol/bind3
Udgave nummer5
Sider (fra-til)473-481
Antal sider9
ISSN2405-500X
DOI
StatusUdgivet - maj 2017

ID: 56381286